Palladian portfolio company Healthcare at Home awarded “Good” CQC rating across all inspection criteria.

The nation’s leading Medicine Services provider, Healthcare at Home, has been rated GOOD by the Care Quality Commission following a recent inspection.

The service, which is the leading pan-European insight based Medicines Service for complex medicines, creates better outcomes for patients by ensuring greater treatment support.

With unparalleled expertise, which has been established through 25 years of in-depth knowledge of patient-medicine behaviour, Healthcare at Home has one million interactions with varied NHS and private patient populations.

Darryn Gibson, Healthcare at Home Chief Executive said: “We are very pleased with our overall ‘Good’ rating which The Care Quality Commission has given us following their inspection at the end of last year.

“Particularly pleasing was the consistency that the business demonstrated across all areas. A rating of GOOD was achieved in every one of the five domains inspected – Safe, Effective, Caring, Responsive and Well-led Services was achieved.

“The report highlights many of the ways in which our dedicated and hardworking teams are providing the best care for our patients, enabling them to have their best day, every day.

“Our main focus at Healthcare at Home is to ensure that we do everything we can to make sure our patients receive the highest level of safe and quality care.  We are investing more resource and capital into state-of-the-art digital healthcare to support and enable more patients to make the most of their treatment allowing them to have their best day, every day.

“This investment in technology will ensure that Healthcare at Home is easy to do business with today, and into the future, helping us to move confidently towards an ‘outstanding’ rating.”

With over 400 specialist nurses employed across the UK, a 24/7 patient advice line and a cold chain logistics operation, Healthcare at Home supports over 180,000 patients per year across 49 therapy areas and 450 chemotherapy regimes.